You appear to be offline. Some data may be unavailable until your connection is restored.
GILD
StockGilead Sciences Inc
Price data not available
Description
Gilead Sciences Inc. is a research‑driven biopharmaceutical company that discovers, develops and markets therapeutic medicines, most notably antiviral drugs for HIV/AIDS, hepatitis B and C, and more recently COVID‑19, as well as oncology, inflammatory and cell‑therapy products. It operates within the biotechnology and pharmaceutical sector, leveraging a strong R&D pipeline and strategic partnerships to bring new treatments to market. Gilead is recognized as a global leader in antiviral therapy, having built a dominant position with flagship HIV regimens and breakthrough hepatitis C cures, and is actively expanding its presence in cancer and specialty disease areas.
Quarterly EarningsQuarterly earnings results, including reported and estimated earnings per share (EPS), for the most recent fiscal quarters.Surprise compares reported EPS with the prior estimate.
| Quarter | DateReport date | EPSReported EPS |
|---|---|---|
| Q4 FY26 | Jan 25, 2027 (est.) | — |
| Q3 FY26 | Oct 29, 2026 | $2.55 |
| Q2 FY26 | Aug 3, 2026 | -$6.75 |
| Q1 FY26 | May 7, 2026 | $2.03 |
| Q4 FY25 | Feb 10, 2026 | $1.86 |
Stay ahead of GILD earnings
Get reminders ahead of GILD's next earnings report, so you always know when results are coming.